A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

January 20, 2021

Study Completion Date

January 20, 2021

Conditions

Healthy

Interventions

BIOLOGICAL

RSV Vaccine

Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.

OTHER

Placebo

Participants will receive a single IM injection of matching placebo on Day 1.

Trial Locations (1)

Souseikai Hakata Clinic, Fukuoka